Last reviewed · How we verify

NCT04499274

Ondansetron and Blood Coagulation

Status unknown NA Last updated 15 March 2023
What this trial tests

NA trial testing 0 ul of ondansetron in Blood Coagulation Disorder in 12 participants. Status unknown.

Timeline
16 September 2020
Primary endpoint
15 November 2023
15 December 2023

Quick facts

Lead sponsorSeoul National University Bundang Hospital
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposebasic science
Enrollment12
Start date16 September 2020
Primary completion15 November 2023
Estimated completion15 December 2023
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Seoul National University Bundang Hospital

Who can join

Adults 20 to 65, any sex, with Blood Coagulation Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ondansetron may alter whole blood coagulation. However, little is known about the dose-response relationships according to the blood concentration of ondansetron. The investigators therefore will perform the present study to measure the effect of ondansestron on the blood coagulation pathway according to the drug concentration level using a thromboelastography test.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Blood Coagulation Disorder

Currently open trials in the same condition.

Other Seoul National University Bundang Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04499274.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing